previously couple of years, the united kingdom has witnessed a revolution in health-related pounds‑decline therapies — in the introduction of semaglutide (Wegovy®) into the developing acceptance of tirzepatide (Mounjaro®). Now, One more name is drawing attention in the two medical and public well